Human Colorectal Cancer
GI Development and Biology
The development of the gastrointestinal system is initiated during gastrulation with the
formation of the primitive gut. The gastrointestinal system begins as an endoderm-lined tube with
three major divisions: the midgut, which opens into the yolk sac; the foregut, which is
continuous with the midgut and extends cranially behind the heart; and the hindgut, which extends
caudally from the midgut. Gastrulation begins at approximately day 17 of human gestation and at
day 7 in the mouse, and by day 22 (day 8 in the mouse) the gut tube is largely closed. The
foregut gives rise to the pharynx, lower respiratory tract, liver, gall bladder, pancreas,
esophagus, stomach, and the duodenum proximal to the opening of the bile duct. The midgut gives
rise to the small intestine (including the duodenum distal to the opening of the bile duct), the
cecum, appendix, ascending colon and the proximal part of the transverse colon. The derivatives
of the hindgut are the distal part of the transverse colon, the descending and sigmoid colon,
the rectum, superior portion of the anal canal, the epithelium of the urinary bladder and most
of the urethra (11,12).
Rapid elongation and movements of the midgut that occur between the sixth and tenth week of
gestation establish the adult orientation of the large and small intestines. By the beginning of
the sixth week (day 10 for mouse embryos), the midgut projects into the umbilical cord. While
within the umbilical cord, the midgut loop rotates 90 degrees bringing the cranial limb of the
loop to the right and the caudal loop to the left. During this rotation, coiling and elongation
of the midgut forms the loops of the small bowel (jejunum and ileum). During the tenth week
(days 15-16 for mouse embryos), the intestine undergoes a further 180-degree rotation as it
returns to the abdomen, establishing the ultimate position of the ascending, transverse and
descending colon with respect to the small intestine (11,12).
The overall histological organization of the digestive system is similar throughout the length
of the tract. The lumen is lined with a mucosa that consists of: epithelium with glandular
invaginations; a supporting layer of loose connective tissue, the lamina propria; and an
underlying layer of smooth muscle, the muscularis mucosae. Submucosal connective tissue surrounds
the mucosa and, in the esophagus and duodenum, contains mucus-secreting glands. Two layers of
smooth muscle, the inner circular layer and the outer longitudinal layer, make up the muscularis
externa that surrounds the submucosa. A simple squamous epithelium, the serosa, covers the outer
surface of the wall except at places where the wall is attached by connective tissue to
neighboring structures. The enteric nervous system consists of the submucosal plexus and the
myenteric plexus that lies between the circular and longitudinal layers of the muscularis
externa. The epithelial lining of most of the digestive tract is derived from the endoderm of
the primitive gut. The muscular and connective tissue components are derived from the splanchnic
mesenchyme surrounding the primitive gut (13,14).
Several anatomical and histological features distinguish the large intestine from other regions
of the digestive tract. There are no villi and plicae circulares, thus the luminal surface of
the mucosa in the colon is smooth, but when the colon is undistended the mucosa and submucosa
exhibit numerous temporary folds. In addition, lymphoid aggregates of varying sizes are located
in the lamina propria and submucosa of the colon wall. The epithelium of the large intestine
contains numerous goblet cells that secrete mucus to lubricate the lumen and facilitate passage
of hardened feces.
For reviews on the molecular basis of gastrointestinal system development see references
15-19.
For additional information about the development and function of the gastrointestinal
system see:
http://www.med.unc.edu
http://calloso.med.mun.ca
|
Tumor Classification and Staging
The classification of tumors is based on the microscopic appearance of hemotoxylin and
eosin-stained tumor sections. The World Health Organization (WHO) tumor classification system
is the most widely accepted schema for the histologic typing of CRC tumors.
WHO Histologic Classification of Tumors of the Colon and Rectum
(Reprinted from Reference 20)
1. Epithelial tumors
1.1 Adenoma
1.1.1 Tubular
1.1.2 Villous
1.1.3 Tubulovillous
1.1.4 Serrated
1.2 Intraepithelial neoplasia (dysplasia) associated with chronic
inflammatory diseases
1.2.1 Low-grade glandular intraepithelial neoplasia
1.2.2 High-grade glandular intraepithelial neoplasia
1.3. Carcinoma
1.3.1 Adenocarcinoma
1.3.2 Mucinous adenocarcinoma
1.3.3 Signet-ring cell carcinoma
1.3.4 Small cell carcinoma
1.3.5 Squamous cell carcinoma
1.3.6 Adenosquamous carcinoma
1.3.7 Medullary carcinoma
1.3.8 Undifferentiated carcinoma
1.4 Carcinoid (well-differentiated endocrine neoplasm)
1.4.1 EC-cell, serotonin-producing neoplasm
1.4.2 L-cell, glucagons-like peptide and PP/PYY- producing tumor
1.4.3 Others
1.5 Mixed carcinoid-adenocarcinoma
1.6 Others
2. Non-epithelial tumors
2.1 Lipoma (benign)
2.2 Leiomyoma (benign)
2.3 Gastrointestinal stromal tumor
2.4 Leiomyosarcoma
2.5 Angiosarcoma
2.6 Kaposi sarcoma
2.7 Malignant melanoma
2.8 Others
2.9 Malignant lymphomas
2.9.1 Marginal zone B-cell lymphoma of MALT Type
2.9.2 Mantle cell lymphoma
2.9.3 Diffuse large B-cell lymphoma
2.9.4 Burkitt lymphoma
2.9.5 Burkitt-like/atypical Burkitt-lymphoma
2.9.6 Others
3. Secondary tumors
4. Polyps
4.1 Hyperplastic (metaplastic)
4.2 Peutz-Jeghers
4.3 Juvenile
CRC can arise spontaneously or in the context of hereditary predispositions such as familial
adenomatous polyposis coli (FAP) or HNPCC (also called Lynch I [colon only] and Lynch II
[colonic and extracolonic involvement] Syndromes). CRC can also arise from dysplasia in
ulcerative colitis. The vast majority of CRCs are adenocarcinomas. Approximately 75% are
located in the colon and 25% are located in the rectum (i.e., below the peritoneal reflection).
The distinction between these two anatomic locations of the primary tumor is important because of
the implications regarding venous drainage and predominant sites of metastases (e.g., liver for
colon; lung for rectum) and the need for additional local therapy following surgical resection
(e.g., chemotherapy with radiotherapy for locally advanced rectal cancer vs. chemotherapy alone
for colon cancers). Non-epithelial tumors such as lymphomas, endocrine tumors, and mesenchymal
tumors are only rarely found in the colon and rectum. A thorough description of the
internationally recognized standard for histological and genetic classification of colorectal
tumors is presented in Hamilton et al. 2000 (20).
CRCs vary in their macroscopic features depending on their location in the colon or rectum and
the stage of the lesion. Carcinomas occurring in the right colon or cecum tend to be bulky
exophytic masses, while those in the left colon are often endophytic and constricting and may
produce colonic obstruction. Those with exophytic growth may be pedunculated, and attached to the
underlying wall by a narrow stalk, or sessile. Signet ring cell carcinomas typically produce a
linitis plastica growth pattern, in which the tumor diffusely infiltrates the bowel wall, with
only subtle thickening of the bowel on gross examination. Carcinomas arising in ulcerative colitis
often arise in plaque-like areas of dysplasia, and exhibit predominantly endophytic growth.
The main precursor lesion of sporadic CRCs is the adenoma. Adenomas vary greatly in size and,
while most are polypoid, depressed and flat lesions also occur. Microscopically, adenomas consist
of columnar epithelial cells with elongated, hyperchromatic, crowded nuclei, with loss of the
normal maturation gradient of the crypt. Typical adenomas are considered low-grade dysplastic
lesions in which nuclear polarity of the neoplastic cells is maintained with respect to the
basement membrane. Progression along the adenoma-carcinoma sequence is often reflected in
morphologic changes. In high-grade dysplasia, neoplastic cells are confined by the basement
membrane to an intact glandular space but show features of tumor progression such as cytologic
features of malignancy, loss of nuclear polarity, and formation of complex glandular outlines.
Foci of Paneth cell, goblet cell, and neuroendocrine cell differentiation may be seen in
adenomas.
 |
 |
| Aberrant Crypt Focus from human colon stained with methylene blue. |
Single crypt adenomas, readily identifiable by the increase in nucleus to cytoplasm ratio and nuclear crowding and hyperchromasia, may be found in
histological sections of grossly normal mucosa in individuals with familial adenomatous polyposis coli. |
The typical sporadic CRC consists of large cribiform glands lined by tall columnar tumor cells
infiltrating a desmoplastic stroma. Invasion of the neoplastic cells into the submucosa and
deeper layers of the bowel wall is necessary for a diagnosis of invasive carcinoma. Lesions
that are similar morphologically, but are confined to intact glandular structures or extend only
into the lamina propria, have little to no risk of metastasis and are referred to as high grade
dysplasia, intramucosal carcinoma, or intramucosal neoplasia. Most CRCs are well to moderately
differentiated adenocarcinomas, with few solid areas. Poorly differentiated adenocarcinomas have
less than 50% recognizable gland formation.
Grading of Colorectal Carcinomas
Grading of colorectal adenocarcinomas is subjective and is thus subject to interobserver variation.
Multiple grading schemes have been proposed, and there is currently no consensus agreement.
The basis of assignment of grade is controversial, with some pathologists basing grade on overall
impression, some on the worst area of the tumor, some on the amount of gland formation, and some
on a combination of features such as gland formation and nuclear grade (Compton CC, Fielding P,
Burgart LJ, et al. Prognostic factors in colorectal cancer: College of American Pathologists
consensus statement. Arch Pathol Lab Med 124: 979-994, 2000).
The Association of Directors of Anatomic and Surgical Pathology has published recommendations
for the reporting of resected colorectal carcinomas (2). Their system is based on a modification
of the WHO classification and is recommended only for adenocarcinomas of no special type:
| Grade |
Description |
| Well differentiated |
Complex or simple tubules; nuclear polarity maintained; minimal nuclear pleomorphism |
| Moderately differentiated |
Complex, simple, or slightly irregular tubules; loss of nuclear polarity |
| Poorly differentiated |
Highly irregular glands; solid areas indicating loss of glandular differentiation; loss of nuclear polarity |
Some groups recommend using a two-tiered grading system formed by collapsing well
and moderately differentiated categories into a single category of low grade, and defining
poorly differentiated and undifferentiated tumors as high grade. This two-tiered system
retains prognostic significance and has the advantage of better reproducibility.
Some of the special types of carcinoma should not be graded by these schemes.
For instance, medullary carcinoma has a solid growth pattern with little glandular
differentiation (3) but generally has a more favorable prognosis than high grade
adenocarcinoma, NOS. It may not be appropriate to grade mucinous carcinomas.
 |
 |
| Typical colorectal adenocarcinoma composed of cribriform glands, often with luminal necrosis. |
Adenocarcinomas arising in ulcerative colitis often invade the colon wall without forming an exophytic mass. |
Several histopathological types of colorectal carcinoma are recognized. Mucinous adenocarcinoma
is a morphologic subtype of colorectal carcinoma in which, greater than 50% of the lesion is
composed of mucin. These tumors, also called colloid carcinoma, contain large pools of
extracellular mucin. Mucinous carcinomas are most often located in the proximal colon. Another
variant, signet-ring carcinoma, also produce abundant mucin that is intracytoplasmic rather than
extracellular. Medullary carcinoma is characterized by a solid growth pattern, relatively little
nuclear pleomorphism, and expansive rather than infiltrative growth, and frequently exhibits
microsatellite instability.
 |
 |
| Medullary carcinoma characterized by tumor cell growth in sheets, with minimal gland formation. Tumor infiltrating lymphocytes are prominent. |
Mucinous carcinoma characterized by large pools of extracellular mucin. |
 |
 |
| Mucinous carcinoma with clusters and strips of tumor cells within the mucin pools. |
Signet-ring cell carcinomas are composed of cells that accumulate intracytoplasmic mucin and infiltrate the stroma in strands or as single cells, with
little gland formation. |
Small-cell undifferentiated carcinoma is a rare but highly aggressive neoplasm that is most
often widely metastatic at presentation. It is characterized by cells with scant cytoplasm with
some signs of neuroendocrine differentiation. Other rare subtypes of human colorectal carcinoma
that have been reported in small series or case reports include: spindle cell, pleomorphic
(giant cell), pigmented, clear cell, stem cell and Paneth cell-rich (crypt cell) carcinoma, and
carcinoma with choriocarcinoma. Mixtures of histopathological subtypes are also observed.
Tumor stage is the most important factor influencing the prognosis of CRC. Two staging systems
are commonly used: one is the American Joint Commission on Cancer (AJCC) staging system
- based on TNM classification of tumors - that divides colorectal cancers into Stages I, II,
III, and IV and the other is the Dukes' staging system that categorizes colorectal cancers into
Stages A, B, C, and D. Stage I (Dukes' Stage A) cancers have not spread beyond the mucosa into the
submucosa or muscularis propria. Stage II (Dukes' Stage B) cancers have invaded through the
muscularis propria and into neighboring tissues (fat or other organs). Stage III (Dukes' Stage C)
cancers have spread to local lymph nodes. Stage IV (Dukes' Stage D) cancers have metastasized to
distant organs.
TNM Classification of tumors of the colon and rectum
(AJCC 2002 TNM System)
T - Primary Tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues
T4 Tumor directly invades other organs or structures and/or perforates visceral peritoneum
N - Regional Lymph Nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in 1 to 3 regional lymph nodes
N2 Metastasis in 4 or more regional lymph nodes
M - Distant Metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage Grouping-TNM Subsets |
| Stage 0 | Tis | N0 | M0 |
| Stage I | T1 | N0 | M0 |
| | T2 | N0 | M0 |
| Stage IIa | T3 | N0 | M0 |
| Stage IIb | T4 | N0 | M0 |
| Stage IIIa | T1 or T2 | N1 | M0 |
| Stage IIIb | T3 or T4 | N1 | M0 |
| Stage IIIc | Any T | N2 | M0 |
| Stage IV | Any T | Any N | M1 |
Table 4. Histopathological Classification of Human Intestinal Tumors and Representative Mouse Models.
| Human Colorectal Tumor |
Comments |
Equivalent Mouse Model |
| Adenocarcinoma |
Most common type; sporadic, & inherited predisposition in FAP |
Apcmin+/-,
Mlh1-/- Apc1638N/+
Msh6-/- Apc1638N/+
Msh3-/- Apc1638N/+
|
| Mucinous carcinoma |
Mucinous component > 50%; associated with HNPCC and microsatellite instability high tumors |
Tgfb1-/- Rag2-/- Smad3-/-
|
| Signet ring cell carcinoma |
>50% signet ring cells |
Smad4+/-
Apc Δ716/+
|
| Adenosquamous carcinoma |
Rare; pure squamous cell carcinoma is very rare |
Not reported |
| Small cell undifferentiated carcinoma |
Neuroendocrine differentiation; highly aggressive |
Not reported |
| Undifferentiated carcinoma |
At least 70% solid growth pattern |
Not reported |
| Medullary carcinoma |
Solid or trabecular growth pattern; little mucin production; tumor-infiltrating lymphocytes; no evidence of neuroendocrine differentiation; HNPCC |
Not reported |
|
Molecular Alterations in CRC
The APC/Wnt Pathway The APC gene was initially identified by positional cloning of
the FAP locus (21,22), and was subsequently found to be mutated in the majority of sporadic
colorectal tumors as well. APC is a large (312 kDa), multifunctional intracellular protein; thus
its inactivation leads to CRC through multiple molecular mechanisms (reviewed in 23-25).
One important function of APC is its regulatory role in the Wingless/Wnt signaling pathway.
APC is part of a protein complex that phosphorylates β-catenin, which marks it for ubiquitination
and subsequent proteolytic degradation. In the presence of the WNT signal, or in the absence of
APC, the complex is destroyed and β-catenin is stabilized and transported to the nucleus.
Inactivation of the APC gene, thus, effectively leads to constitutive activation of the WNT
pathway and, consequently, the accumulation of β-catenin in the nucleus. In the nucleus,β-catenin complexes with DNA-binding proteins of the T-cell factor (TCF) family and acts as a
co-activator of transcription of several genes involved with proliferation, apoptosis and
cell-cycle progression including MYC, cyclin D, matrilysin, CD44 and the urokinase-type
plasminogen activator receptor (26-29). Altered expression of these downstream targets of the
β-catenin signaling pathway has been implicated in tumor progression, invasion and
metastasis.
APC inactivation may also contribute to tumor progression by promoting chromosomal instability
(CIN). APC has two identified functions in mitosis: the promotion of proper attachment of the
kinetochore to the mitotic spindle and the regulation of centrosome duplication via interactions
with tubulin and the centrosome (30). Two types of chromosomal abnormalities are often observed
in APC-deficient cells: quantitative effects (tetraploidy) due to non-disjunction, and
chromosomal translocations due to multipolar spindles (31). CIN leads to an accumulation of
additional mutations that accelerates malignant progression (24).
The TGFβ Pathway There are several lines of evidence suggesting that alterations in
the TGFβ signaling pathway play a role the development of CRC. Cell lines derived from human
colon tumors are often resistant to the growth-inhibitory effects of TGF-β1, and this resistance
is associated with increased invasiveness (32,33). Mutations in TGFβ receptor type II (TGFβRII)
are present in both sporadic and inherited colon cancers that exhibit microsatellite instability
(34-36). Inactivating mutations in SMAD2 and SMAD4, that encode intracellular proteins involved
in the transduction of the TGFβ signal, are also present in human colon cancer (37-39).
TGFβ signaling is multifunctional; consequently there are several mechanisms by which the loss of
TGFβ function could contribute to the initiation, promotion or progression of CRC. TGFβ1 inhibits
epithelial cell growth in vitro and the absence of this inhibition may enhance tumor cell
proliferation in vivo. In addition, TGFβ plays a role in remodeling of the extracellular matrix;
thus the disruption of TGFβ function may also lead to the dysregulation of tumor cell-matrix
interactions and epithelial cell differentiation (40). Lastly, TGFβ1 is a potent regulator of
immune and inflammatory cell responses and the disruption of this function could lead to a lack
of inhibition of the local production of growth factors as well as tissue damage induced by free
radicals (41).
DNA Mismatch Repair Deficiency The MMR system in cells functions to correct mismatched base pairs
and insertion/deletion loops that arise during DNA synthesis. HNPCC is caused by an inherited
mutation in any one of the five human MMR genes; MSH2, MLH1, MSH6, PMS2 and PMS1 (42). In HNPCC,
MMR gene inactivation results from germline mutation of one allele, followed by LOH of the second
allele. Microsatellite instability (MSI), an indicator of MMR deficiency, occurs in essentially
all HNPCC-related tumors, and approximately 15% of sporadic tumors. In sporadic tumors with MSI,
MMR deficiency is due to an epigenetic mechanism, hypermethylation of the promoter region of a
single MMR gene, MLH1 (10).
Dysfunction of the MMR system affects important growth-regulatory genes that are known to be
involved in the development of colorectal tumors (e.g. APC, K-RAS and p53), and genes with
mononucleotide repeats in their coding regions (e.g. TGFbRII, insulin-like growth factor II receptor
, and BAX, a proapoptotic gene) are particularly vulnerable to increased mutation rates
(43-45). MMR proteins have other functions related to DNA damage signaling and apoptosis that
may also be relevant to tumorigenesis (reviewed in 42).
Tumors with a high frequency of MSI (termed MSI-high) exhibit histologic features of aggressive
tumors but are paradoxically associated with a significant survival advantage that is independent
of tumor stage or lymph node involvement (46). Certain histologic subtypes, such as medullary
carcinoma and mucinous carcinoma, are over-represented among MSI-high tumors.
|
Novel Therapeutics
Fluorouracil (5-FU) was for many years the only effective chemotherapy drug for CRC, however,
primary resistance to 5-FU is observed in approximately 30% of patients with metastatic colorectal
cancer and nearly all patients will ultimately develop secondary resistance. In recent years, new
therapeutic options have emerged (such as Mitomycin C (MMC), oxaliplatin, irinotecan, and oral
fluoropyrimidines such as capecitabine that enhance the efficacy of 5-FU when used in
combination chemotherapy regimens. With the availability of new drugs with activity against CRC,
many current randomized trials are focused on comparing different combination chemotherapy
regimens to optimize the balance between efficacy and toxicity.
MMC (an inhibitor of DNA synthesis), like irinotecan, was initially identified for use as
second-line therapy. Recently, MMC has been evaluated as first-line treatment for advanced CRC in
combination with 5-FU in a phase III clinical trial and shown to be superior with respect to
response rates and overall survival to 5-FU alone (47).
Oxaliplatin (LOHP, Eloxatine) is a platinum analog that binds to guanine residues of DNA and
interferes with DNA replication and transcription. While still controversial, preliminary studies
have shown that combination therapy with 5-FU, leucovorin, and irinotecan (IFL) or oxaliplatin is
more active than 5FU, and leucovorin alone (48). Results of a large randomized trial of
oxaliplatin, 5-FU and leucovorin combination therapy in patients with CRC that has relapsed after
first-line IFL are expected in the fall of 2002. Oxaliplatin is currently under review by the US
Food and Drug Administration and, if found to be sufficiently safe and effective, may become
commercially available in the United States by the end of the year.
Agents that disrupt the molecular pathways of carcinogenesis have the potential to direct
cellular toxicity to the tumor while sparing normal cells. With increased understanding of these
pathways, biological therapies that specifically target them are becoming increasingly prevalent
in clinical trials of new CRC treatments. One example involves agents that block the signaling
activity of the epidermal growth factor (EGF) receptor. The EGF receptor (EGFR) is overexpressed
in many epithelial tumors and its level of expression is inversely correlated with survival (49).
Phase I/II trials have shown that C225, a monoclonal antibody that blocks EGFR function, in
combination with chemotherapy, has activity against chemotherapy-resistant cancers (50). ZD1839
(Iressa), a pharmacological inhibitor of EGFR tyrosine kinase activity, is currently being
tested in a phase II clinical trial.
The prevention of tumor angiogenesis is another important therapeutic strategy that is being
tested in many types of cancer. Vascular endothelial growth factor (VEGF) plays an important role
in normal and tumor angiogenesis. A recent phase II study suggests that a monoclonal antibody
against VEGF in combination with chemotherapy has greater efficacy in treating metastatic CRC
compared to chemotherapy alone (51).
Cyclooxygenase (COX) converts arachidonic acid into prostaglandins and other prostanoids that
enhance carcinogenesis by promoting cell proliferation, inhibiting apoptosis, and promoting tumor
angiogenesis (reviewed in 52). The COX-2 isoform is overexpressed in a wide variety of neoplasms,
including CRC (53). Targeted disruption of the COX-2 gene in APCD716 mice (a model for FAP)
reduced the number and size of intestinal polyps by nearly 80% (54), providing a dramatic
demonstration of the causal relationship between COX-2 and colorectal tumorigenesis. Recent
human studies have shown that COX-2 inhibitors can prevent polyps in FAP patients (55).
Preliminary data from a multi-center phase II trial of STI571 (Gleevec), an inhibitor of the
BCR-ABL tyrosine kinase and the receptor tyrosine kinases for platelet-derived growth factor
(PDGF) and c-kit, suggests that this drug is efficacious for treating patients with unresectable
or metastatic gastrointestinal stromal tumors (GIST; 56). Other novel agents with potential
activity against CRC that are currently in clinical trials include immunotherapy agents to
stimulate immune rejection of residual tumor cells and farnesyl transferase inhibitors, which
prevent Ras activation (reviewed in 57).
For a more complete listing of drugs currently in development and ongoing clinical trials see:
http://www.cancer.gov/search/clinical_trials/
|
|